• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agency of Health Technology Assessment of Uruguay
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canada’s Drug Agency (CDA-AMC)
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Healthcare Quality Institute
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Regione Emilia Romagna
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [25249 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2003     National Institute for Health and Care Excellence (NICE) Radiofrequency ablation of varicose veins. NICE HealthTech guidance 3
2001     HAYES, Inc. Radiofrequency catheter ablation
1999     Alberta Heritage Foundation for Medical Research (AHFMR) Radiofrequency catheter ablation 64 electrode basket catheter
2002     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Radiofrequency catheter ablation for cardiac arrhythmias: a clinical and economic review
2008     Blue Cross Blue Shield Association (BCBS) Radiofrequency catheter ablation of the pulmonary veins for treatment of atrial fibrillation
2005     Institute for Clinical Effectiveness and Health Policy (IECS) Radiofrequency catheter ablation technique in atrial fibrillation
2012     National Institute for Health and Care Excellence (NICE) Radiofrequency cold ablation for respiratory papillomatosis. NICE HealthTech guidance 295
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Radiofrequency denervation for lumbar and cervical facet joint pain – a systematic review
2023     National Institute for Health and Care Excellence (NICE) Radiofrequency denervation for osteoarthritic knee pain. NICE HealthTech guidance 686
2016     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Radiofrequency denervation for sacroiliac and facet joint pain
1997     Health Council of the Netherlands Gezondheidsraad (GR) Radiofrequency electromagnetic fields (300 Hz - 300 GHz)
2004     HAYES, Inc. Radiofrequency endometrial ablation for menorrhagia secondary to dysfunctional uterine bleeding
2017     HAYES, Inc. Radiofrequency nerve ablation for treatment of plantar fasciitis
2006     Canadian Agency for Drugs and Technologies in Health (CADTH) Radiofrequency neurotomy for lumber pain
2012     Malaysian Health Technology Assessment (MaHTAS) Radiofrequency neurotomy of genicular nerve of both knees
2025     The Regional Health Technology Assessment Centre (HTA-centrum) Radiofrequency or microwave ablation versus surgery for treatment of benign non-toxic or toxic nodules, and toxic diffuse autoimmune hyperthyroidism (Graves' disease)
2005     Institute for Clinical Effectiveness and Health Policy (IECS) Radiofrequency techniques for the management of lumbar discopathy (discal nucleoplasty, percutaneous thermocoagulation, electrothermal annuloplasty)
2014     National Institute for Health and Care Excellence (NICE) Radiofrequency tissue reduction for turbinate hypertrophy. NICE HealthTech guidance 343
2006     HAYES, Inc. Radiofrequency tissue volume reduction (RFTVR) for the treatment of upper airway obstruction
2007     HAYES, Inc. Radiofrequency tissue volume reduction for the treatment of upper airway obstruction
2017     National Institute for Health and Care Excellence (NICE) Radiofrequency treatment for haemorrhoids. NICE HealthTech guidance 447
1999     Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) Radiofrequency treatment for liver and osseous metastasis (systematic review, expert panel)
2004     National Institute for Health and Care Excellence (NICE) Radiofrequency valvotomy for pulmonary atresia. NICE HealthTech guidance 57
2000     HAYES, Inc. Radiofrequency volumetric tissue reduction for the treatment of upper airway obstruction
2007     National Institute for Health and Care Excellence (NICE) Radiofrequency-assisted liver resection. NICE HealthTech guidance 136
2020     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Radiofrequency-Induced Intravesical Chemohyperthermia for Non-Muscle-Invasive Bladder Cancer
2009     Canadian Agency for Drugs and Technologies in Health (CADTH) Radioimmunotherapies for non-hodgkin lymphoma: systematic review of clinical effectiveness, cost-effectiveness, and guidelines
2009     Canadian Agency for Drugs and Technologies in Health (CADTH) Radioimmunotherapies for non-hodgkin lymphoma: systematic review of clinical effectiveness, cost-effectiveness, and guidelines
2013     HAYES, Inc. Radioiodinated metaiodobenzylguanidine (131I-MIBG) targeted radiation therapy for refractory or relapsed neuroblastoma
2003     Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) Radiological bucky tables with a CCD camera - systematic review, primary research, expert panel
2024     Agency for Care Effectiveness (ACE) Radiolucent fixation rods & screws for patients with primary and metastatic spinal tumours
2001     Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) Radionuclide therapy- systematic review, expert panel
1997     Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) Radiosurgery (systematic review, working group, expert panel)
1997     Alberta Heritage Foundation for Medical Research (AHFMR) Radiosurgery in the treatment of malignant melanoma
2004     National Institute for Health and Care Excellence (NICE) Radiotherapy for age-related macular degeneration. NICE HealthTech guidance 24
2003     The Swedish Council on Health Technology Assessment (SBU) Radiotherapy for cancer
1999     Healthcare Insurance Board/ College Voor Zorgverzekeringen (CVZ) Radiotherapy in bone metastasis - primary research
1996     The Swedish Council on Health Technology Assessment (SBU) Radiotherapy in Sweden [2 vols.]
2014     Agency for Healthcare Research and Quality (AHRQ) Radiotherapy treatments for head and neck cancer update
2014     Medical Services Advisory Committee (MSAC) Radium 223 for the treatment of patients with symptomatic castrate resistant prostate cancer with skeletal metastases
2016     National Institute for Health and Care Excellence (NICE) Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases. NICE technology appraisal guidance 412
2014     NIHR Health Technology Assessment programme Radium-223 dichloride for treating metastatic hormone relapsed prostate cancer with bone metastases
2017     HAYES, Inc. Raindrop near vision inlay (ReVision Optics Inc.) for presbyopia
2005     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Raloxifene for primary and secondary prevention of osteoporotic fractures in postmenopausal women: a systematic review of efficacy and safety evidence
1999     ECRI Raloxifene, a selective estrogen receptor modulator [SERM] for prevention of postmenopausal osteoporosis
2015     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Raltegravir (Isentress®)
2013     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Raltegravir (Isentress®)
2008     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Raltegravir (Isentress®) in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in treatment-experienced adult patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy
2010     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Raltegravir (Isentress®) in combination with other antiretrovirals for the treatment of HIV-1 infection in adults
2012     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Ramipril 2.5 mg/5 ml oral solution
2014     NIHR Horizon Scanning Centre (NIHR HSC) Ramucirumab (Cyramza) in combination with docetaxel for locally advanced or metastatic non-small cell lung cancer – second line
2013     NIHR Horizon Scanning Centre (NIHR HSC) Ramucirumab for hepatocellular cancer – second line
2014     NIHR Horizon Scanning Centre (NIHR HSC) Ramucirumab for metastatic colorectal cancer – second line
2016     National Institute for Health and Care Excellence (NICE) Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer. NICE technology appraisal guidance 403
2016     National Institute for Health and Care Excellence (NICE) Ramucirumab for treating advanced gastric cancer or gastrooesophageal junction adenocarcinoma previously treated with chemotherapy. NICE technology appraisal guidance 378
2019     National Institute for Health and Care Excellence (NICE) Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal). NICE technology appraisal guidance 609
2015     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Ramucirumab in combination with paclitaxel as second-line treatment for adult patients with advanced gastric or gastro-oesophageal junction carcinoma
2014     NIHR Horizon Scanning Centre (NIHR HSC) Ramucirumab in combination with paclitaxel for advanced gastric cancer and gastro-oesophageal junction adenocarcinoma after prior chemotherapy
2013     NIHR Horizon Scanning Centre (NIHR HSC) Ramucirumab monotherapy for advanced gastric cancer and gastro-oesophageal junction adenocarcinoma – after prior chemotherapy
2020     National Institute for Health and Care Excellence (NICE) Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal). NICE technology appraisal guidance 635
2013     NIHR Health Technology Assessment programme Randomised Assessment of Treatment using Panel Assay of Cardiac markers - Contemporary Biomarker Evaluation (RATPAC CBE)
2006     NIHR Health Technology Assessment programme Randomised clinical trial, observational study and assessment of cost-effectiveness of the treatment of varicose veins (REACTIV trial)
2024     NIHR Health Technology Assessment programme Randomised control trial of surveillance and no surveillance for patients with Barrett's oesophagus - BOSS (Barrett's Oesophagus Surveillance Study)
2005     NIHR Health Technology Assessment programme Randomised controlled multiple treatment comparison to provide a cost-effectiveness rationale for the selection of antimicrobial therapy in acne
2017     NIHR Health Technology Assessment programme Randomised controlled trial and economic analysis of an internet-based weight management programme: POWeR+ (Positive Online Weight Reduction)
2017     NIHR Health Technology Assessment programme Randomised controlled trial and economic analysis of an internet-based weight management programme: POWeR+ (Positive Online Weight Reduction)
2014     NIHR Health Technology Assessment programme Randomised controlled trial and health economic evaluation of the impact of diagnostic testing for influenza, respiratory syncytial virus and Streptococcus pneumoniae infection on the management of acute admissions in the elderly and high-risk 18- to 64-year olds
2014     NIHR Health Technology Assessment programme Randomised controlled trial and health economic evaluation of the impact of diagnostic testing for influenza, respiratory syncytial virus and Streptococcus pneumoniae infection on the management of acute admissions in the elderly and high-risk 18- to 64-year-olds
2010     NIHR Health Technology Assessment programme Randomised controlled trial and parallel economic evaluation of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR)
2010     NIHR Health Technology Assessment programme Randomised controlled trial and parallel economic evaluation of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR)
2017     NIHR Health Technology Assessment programme Randomised controlled trial evaluating the effectiveness and cost-effectiveness of 'Families for Health', a family-based childhood obesity treatment intervention delivered in a community setting for ages 6 to 11 years
2017     NIHR Health Technology Assessment programme Randomised controlled trial evaluating the effectiveness and cost-effectiveness of 'Families for Health', a family-based childhood obesity treatment intervention delivered in a community setting for ages 6 to 11 years
2000     NIHR Health Technology Assessment programme Randomised controlled trial of non-directive counselling, cognitive-behaviour therapy and usual general practitioner care in the management of depression as well as mixed anxiety and depression in primary care
2017     NIHR Health Technology Assessment programme Randomised controlled trial of silk therapeutic garments for the management of atopic eczema in children: the CLOTHES trial
2017     NIHR Health Technology Assessment programme Randomised controlled trial of silk therapeutic garments for the management of atopic eczema in children: the CLOTHES trial
2005     NIHR Health Technology Assessment programme Randomised controlled trial of the cost-effectiveness of water-based therapy for lower limb osteoarthritis
2009     NIHR Health Technology Assessment programme Randomised controlled trial of the use of the three dressing preparations in the management of chronic ulceration of the foot in diabetes
2014     NIHR Health Technology Assessment programme Randomised controlled trial of Tumour necrosis factor inhibitors Against Combination Intensive Therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews
2009     NIHR Health Technology Assessment programme Randomised controlled trial to determine the clinical and cost-effectiveness of selective serotonin reuptake inhibitors plus supportive care, versus supportive care alone, for mild to moderate depression with somatic symptoms in primary care. The THREAD (THREshold for AntiDepressant response) study
2010     NIHR Health Technology Assessment programme Randomised controlled trials for policy interventions: a review of reviews and meta-regression
2006     NIHR Health Technology Assessment programme Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment
2005     NIHR Health Technology Assessment programme Randomised evaluation of alternative electrosurgical modalities to treat bladder outflow obstruction in men with benign prostatic hyperplasia
2009     NIHR Health Technology Assessment programme Randomised preference trial of medical versus surgical termination of pregnancy less than 14 weeks' gestation (TOPS)
2008     NIHR Health Technology Assessment programme Randomised trial of fluoxetine and cognitive-behavioral therapy versus fluoxetine alone in adolescents with persistent major depression - primary research
2005     Agency for Healthcare Research and Quality (AHRQ) Randomized trials of secondary prevention programs in coronary artery disease: a systematic review
2015     NIHR Horizon Scanning Centre (NIHR HSC) Ranibizumab (Lucentis) for choroidal neovascularisation and macular oedema
2009     NIHR Horizon Scanning Centre (NIHR HSC) Ranibizumab (Lucentis) for diabetic macular oedema
2009     NIHR Horizon Scanning Centre (NIHR HSC) Ranibizumab (Lucentis) for macular oedema secondary to central or branch retinal vein occlusion
2008     HAYES, Inc. Ranibizumab (Lucentis) for neovascular age-related macular degeneration
2011     NIHR Horizon Scanning Centre (NIHR HSC) Ranibizumab (Lucentis) for visual impairment due to choroidal neovascularisation (CNV) secondary to pathological myopia - first line
2008     NIHR Health Technology Assessment programme Ranibizumab and pegaptanib for the treatment of age-related macular degeneration - technology assessment report for NICE, ref 04/24/01
2008     NIHR Health Technology Assessment programme Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation
2005     NIHR Horizon Scanning Centre (NIHR HSC) Ranibizumab for age-related macular degeneration - horizon scanning review
2013     NIHR Health Technology Assessment programme Ranibizumab for the treatment of choroidal neovascularisation associated with pathological myopia
2011     NIHR Health Technology Assessment programme Ranibizumab for the treatment of diabetic macular oedema
2011     NIHR Health Technology Assessment programme Ranibizumab for the treatment of macular oedema caused by retinal vein occlusion (RVO): a single technology appraisal
2015     Medical Services Advisory Committee (MSAC) Ranibizumab for the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (RVO)
2022     Agency for Care Effectiveness (ACE) Ranibizumab for treating age-related macular degeneration, diabetic macular oedema and retinal vein occlusion
2013     National Institute for Health and Care Excellence (NICE) Ranibizumab for treating choroidal neovascularisation associated with pathological myopia. NICE technology appraisal guidance 298
2013     National Institute for Health and Care Excellence (NICE) Ranibizumab for treating diabetic macular oedema. NICE technology appraisal guidance 274